La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Hubei Biocause Heilen Pharmaceutical Bilan de santé
Santé financière contrôle des critères 6/6
Hubei Biocause Heilen Pharmaceutical has a total shareholder equity of CN ¥2.4B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥2.5B and CN¥147.3M respectively. Hubei Biocause Heilen Pharmaceutical's EBIT is CN¥132.4M making its interest coverage ratio -2.5. It has cash and short-term investments of CN¥1.8B.
Informations clés
0%
Ratio d'endettement
CN¥0
Dette
| Ratio de couverture des intérêts | -2.5x |
| Argent liquide | CN¥1.78b |
| Fonds propres | CN¥2.39b |
| Total du passif | CN¥147.33m |
| Total des actifs | CN¥2.54b |
Mises à jour récentes de la santé financière
Pas de mise à jour
Recent updates
Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211)
Aug 07
Hubei Biocause Heilen Pharmaceutical (SZSE:301211) Will Pay A Larger Dividend Than Last Year At CN¥0.48
May 22Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Promising Earnings May Rest On Soft Foundations
Apr 29Analyse de la situation financière
Passif à court terme: 301211's short term assets (CN¥2.1B) exceed its short term liabilities (CN¥133.3M).
Passif à long terme: 301211's short term assets (CN¥2.1B) exceed its long term liabilities (CN¥14.0M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: 301211 is debt free.
Réduire la dette: 301211 has no debt compared to 5 years ago when its debt to equity ratio was 20.9%.
Couverture de la dette: 301211 has no debt, therefore it does not need to be covered by operating cash flow.
Couverture des intérêts: 301211 has no debt, therefore coverage of interest payments is not a concern.